FundraiseBase by

CREATE Medicines

Raised $122M in a Series B round, announced 14 May 2026.

Round

CREATE Medicines announced a $122 million Series B to advance its in vivo CAR pipeline.

Amount: $122M
Stage: Series B
Announced: 14 May 2026
Leads: Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners
Other investors: Alexandria Venture Investments
Use of funds: Advancing CD19 in vivo CA
Checked: Amount and date checked against the press source

Company

Develops in vivo CAR cell therapies targeting autoimmune disease and oncology.

Based in: Cambridge
Founded: 2021
Sector: Health
Website: createmedicines.com ↗

Founders

Daniel GettsChief Executive Officer
Ronald Valeco-founder
Siddhartha Mukherjeeco-founder

Sources and links

Source: CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disea news.google.com
Website: createmedicines.com ↗

Just raised?

MediaBoost gets your round in front of the press, future hires and your next investors.

Announce your round with MediaBoost